Transcriptional regulation of NK cell state by ELF4 links innate immune licensing to kidney fibrosis
Journal of Clinical Investigation · 12.11.2026
DOI: 10.1172/jci208155 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 12.11.2026. Verfasst von Shen Li und 18 weiteren Autor:innen. Beteiligte Einrichtung: Renal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United …. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Fibrosis is a common outcome of chronic tissue injury, yet immune regulators that are conserved across species and translatable to human disease remain poorly defined. By integrating human kidney transcriptomes with multiple murine models of kidney fibrosis, we identified the ETS transcription factor ELF4 as a conserved, immune-enriched regulator associated with disease severity. ELF4 expression was highest in natural killer (NK) cells. Genetic deletion of Elf4 , including NK cell–specific ablation, attenuated experimental kidney injury, with reduced inflammation, fibrosis, and loss of renal function. Single-cell and functional analyses showed that ELF4 deficiency disrupts late-stage NK cell maturation and broadly suppresses cytotoxic and interferon-γ (IFNγ) effector programs. Mechanistically, ELF4 directly sustains STAT1 transcription, maintaining a STAT1–TBX21 program required for NK cell maturation and effector competence. Consistent with this framework, NK cell depletion, IFNγ neutralization, or antisense-mediated suppression of Elf4 phenocopied renal protection. Together, these findings identify ELF4 as a transcriptional licensing factor that links NK cell state to kidney injury and highlight innate immune programming as a potential therapeutic entry point in chronic kidney disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Renal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America.
- Department of Pathobiology, University of Pennsylvania, School of Veterinary Medicine, Philadelphia, United States of America.
- Center for Cellular Immunotherapies, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America.
- Ionis Pharmaceuticals Inc., Carlsbad, United States of America.
- Division of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, United States of America.
- CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Aix Marseille Université, Marseille, France.
Förderung
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Li, S., Hu, H., Lanzar, Z. R., Gu, X., Cruz-Morales, E., Bochi-Layec, A. C., Sanchez-Navarro, A., Park, J., Shrestha, R., Liu, H., Donner, A. J., Lin, M. H., Bell, T. A., Miner, J. H., Ruella, M., Vivier, E., Lucas, C. L., Hunter, C. A., & Susztak, K. (2026). Transcriptional regulation of NK cell state by ELF4 links innate immune licensing to kidney fibrosis. Journal of Clinical Investigation. https://doi.org/10.1172/jci208155
Vancouver
Li S, Hu H, Lanzar ZR, Gu X, Cruz-Morales E, Bochi-Layec AC, et al. Transcriptional regulation of NK cell state by ELF4 links innate immune licensing to kidney fibrosis. Journal of Clinical Investigation. 2026. doi:10.1172/jci208155
BibTeX
@article{Li2026,
author = {Li, Shen and Hu, Hailong and Lanzar, Zachary R and Gu, Xiangchen and Cruz-Morales, Elisa and Bochi-Layec, Audrey C and Sanchez-Navarro, Andrea and Park, Jihwan and Shrestha, Rojesh and Liu, Hongbo and Donner, Aaron J and Lin, Meei-Hua and Bell, Thomas A and Miner, Jeffrey H and Ruella, Marco and Vivier, Eric and Lucas, Carrie L and Hunter, Christopher A and Susztak, Katalin},
title = {Transcriptional regulation of NK cell state by ELF4 links innate immune licensing to kidney fibrosis},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci208155}
}
EUVIMED